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Passive immunisation of convalescent human anti-Zika plasma
protects against challenge with New World Zika virus in
cynomolgus macaques
Neil Berry 1✉, Sarah Kempster1, Claire Ham1, Adrian Jenkins1, Jo Hall1, Mark Page 2, Giada Mattiuzzo 2, Yemisi Adedeji1,
Roger Hewson 3, Elaine Giles1, Debbie Ferguson1 and Neil Almond1
Zika virus (ZIKV) causes neurological complications in susceptible individuals, highlighted in the recent South American epidemic.
Natural ZIKV infection elicits host responses capable of preventing subsequent re-infection, raising expectations for effective
vaccination. Defining protective immune correlates will inform viral intervention strategies, particularly vaccine development. Non-
human primate (NHP) species are susceptible to ZIKV and represent models for vaccine development. The protective efficacy of a
human anti-ZIKV convalescent plasma pool (16/320-14) developed as a candidate reference material for a WHO International
Standard was evaluated in macaques. Convalescent plasma administered to four cynomolgus macaques (Macaca fascicularis) intra-
peritoneally 24 hrs prior to sub-cutaneous challenge with 103 pfu ZIKVPRVABC59 protected against detectable infection, with absence
of detectable ZIKV RNA in blood and lymphoid tissues. Passively immunised anti-ZIKV immunoglobulin administered prior to time
of challenge remained present only at very low levels 42 days post-challenge. Absence of de novo antibody responses in passively
immunised macaques indicate sterilising immunity compared with naïve challenge controls that exhibited active ZIKV-specific IgM
and IgG responses post-challenge. Demonstration that the presence of convalescent anti-ZIKV at levels of 400 IU/mL neutralising
antibody protects against virus challenge provides a scientific framework for development of anti-ZIKV vaccines and facilitates
regulatory approval.
npj Vaccines            (2020) 5:86 ; https://doi.org/10.1038/s41541-020-00234-y
INTRODUCTION
Zika virus (ZIKV) is a Flavivirus and newly re-emergent human
pathogen now prevalent in parts of Central and South America1,
having spread from Africa and Asia across the Pacific Ocean in the
previous decade2. In 2015, ZIKV erupted as a major epidemic in
South and Central America, subsequently identified as a global
Public Health Emergency of International Concern by the World
Health Organisation (WHO). In South America, ZIKV was linked to
significant neurological complications, notably microcephaly, in
children born to Zika positive mothers3–6 and a range of
peripheral neuropathy conditions in adults including Guillain-
Barre Syndrome7,8. International initiatives were established to
better understand virus pathogenesis and develop strategies to
combat future outbreaks. Studies conducted in different NHP
species have elucidated pathogenesis whereby ZIKV is no longer
regarded simply as a self-limiting acute infection but persisting
viral signals have been detected in multiple anatomical sites many
weeks after the initial infection has cleared from the blood9–16.
ZIKV has a broad host range capable of productively infecting a
spectrum of higher mammals including humans and both Old and
New World monkey species16,17. Antibody responses to major viral
proteins (e.g., NS-1 and envelope antigens), particularly a broadly
neutralising antibody response, are associated with recovery from
ZIKV infection that appears to confer protective immunity against
re-infection, with a lack of new infections in exposed, immune
populations as confirmed by epidemiological studies18. Studies
conducted in NHP species have also formally demonstrated
resistance to superinfection in these susceptible hosts9. Moreover,
ZIKV immunity appears effective against both African and Asian
lineage strains19,20, hence considerable optimism exists for
vaccine-induced immunity to protect against ZIKV infection and
disease.
Experimental studies using interferon-deficient knockout mice
and other strains, have also demonstrated protective efficacy of
human neutralising antibodies against infection and subsequent
development of microcephaly21. Immunodeficient mouse models
remain informative despite lacking the ability to fully recapitulate
systemic ZIKV infection of immunocompetent hosts, to provide
indications of vaccine efficacy22. However, due to anatomical
differences between NHPs and rodents, including differences in
placental structure, comparative pathogenesis studies conducted
in multiple NHP species, including New World hosts, suggest
higher order mammals may more faithfully reproduce human ZIKV
infection and associated immune responses16,17.
Whilst there is strong evidence that anti-Zika immune sera may
protect, the challenge of measuring the amount of antibody
required in a robust comparative manner has prevented clear
statements on how strong an anti-ZIKV response is required for
vaccine success. Recently a reference material, the 1st WHO
International Standard for anti-Asian lineage ZIKV antibody was
established to harmonise measurement of these antibodies23.
Here, we demonstrate that a human anti-Zika convalescent
plasma pool calibrated as part of that study passively protected
cynomolgus macaques (Macaca fascicularis) against challenge
with South American-derived Asian lineage ZIKV. Our results
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provide a framework that supports not only vaccine development
but also their early regulatory approval.
RESULTS
Standardisation of RT-qPCR assays to detect ZIKV RNA in plasma
To evaluate viral load determinations, data obtained with the RT-
qPCR assay were expressed in both ZIKV RNA copies/mL and
International Units/ml (IU/mL). Standard curves were generated
for both using a plasma RNA series as previously described16 and
the secondary ZIKV International RNA working reagent (desig-
nated NIBSC 16/110) prepared from propagation of the Ugandan
1962 MP1751 strain24. This material had been calibrated against
the 1st WHO IS for ZIKV RNA as part of an international
collaborative study to contain 6.75 IU/mL log10
25.
Initially, ZIKV RNA values were determined using the ZIKVPRVABC59
reference virus grown on Vero cells and supernatant virus diluted
in negative macaque plasma, generating a standard curve as
shown in Fig. 1. In parallel regression analyses, data derived from
the external QC material were compared, following serial dilution
in macaque-negative plasma. There was a high degree of
agreement with parallel regression curves generated for each
preparation. Hence, it was possible to convert the ZIKV RNA
copies/ml data into IU/mL by interpolation. In this manner, ZIKV
RNA could be expressed as RNA equivalents against the WHO
measurement system. The limit of detection (LOD) of this assay
was determined to be 50 ZIKV RNA copies/mL with the input
plasma volume described. Comparable LOD of 50 ZIKV RNA IU/mL
were determined by parallel regression analysis which further
indicated the RT-qPCR assay to be equally efficient in determining
ZIKV RNA values from both African and Asian lineage viruses.
Immune transfer
Four juvenile cynomolgus macaques were administered human
anti-ZIKV polyclonal convalescent plasma via the intra-peritoneal
(i.p.) route. The infused material had been prepared from multiple
vials of the anti-ZIKV working reagent (NIBSC 16/320). In the
international collaborative study that established the 1st Interna-
tional Standard for anti-Asian lineage ZIKV antibodies, the material
was determined to have an anti-ZIKV neutralising antibody titre of
2230 NT50/mL. Analysis of the study assigned a value of 2756 IU/
mL (95% confidence limits of 2003 to 3792 IU/mL) to this
preparation22. Subsequently, all neutralisation assay data were
expressed as a relative potency in IU/mL. Assuming the blood
volume/weight ratio of this species is ~66 mL/kg, if 100% antibody
was taken up from the peritoneum with no antibody clearance
before virus challenge 24 h later, ~76% (±5%) of anti-ZIKV
antibody administered i.p. was detected in blood 24 h later. No
adverse effects were detected as a result of the immune transfer
procedures, with no detectable serum sickness or similar clinical
presentations.
ZIKV RNA is undetectable in blood and tissues of antibody-treated
macaques compared with controls
The primary infection outcome of this study was determined by
RT-qPCR analysis of ZIKV RNA levels in plasma. Data for the four
untreated, control cynomolgus macaques (R5, R11, R12, R13) are
shown in Fig. 2a, with an acute phase viraemia of ~104.5 peaking
3–5 days post inoculation. This is in keeping with previously
published findings of ZIKV plasma kinetics in this species16. The
distribution and levels of ZIKV cell associated-RNA detected at
5 weeks p.i. broadly reflected the acute-phase vRNA kinetics (Fig.
2b). R13 and R11 exhibited the lowest peak vRNA with ZIKV cell-
associated RNA sporadically detectable in tissues. R5 and R12,
which displayed higher peak plasma vRNA exhibited comparably
higher tissue cell-associated RNA loads. The slightly delayed but
sustained peak in R12 appeared to be reflected in a proportio-
nately higher level of virus replication in the MLN.
In macaques pre-treated with the convalescent antibody
preparation there was no evidence of ZIKV RNA detected either
as cell-free viral RNA in plasma or sequestered cell-associated viral
RNA in key lymphoid tissues in samples collected at termination
(Fig. 2c, d). In blood, there was no evidence of late appearance or
delayed viral kinetics (vRNA blips) at subsequent time-points,
indicating complete virus suppression at the anticipated time of
the acute-phase viraemia. This is further supported by lack of
detectable ZIKV genome in any tissue analysed by cell associated-
RNA RT-qPCR representing key tissues of the spleen, the iliac, and
brachial (peripheral) lymph nodes, or mesenteric, salivary gland
and genital lymph nodes. In naïve challenge controls, each of
these tissues were genome positive in at least one subject. Lack of
detectable virus at any time point in treated macaques under-
scores the complete suppression of the ZIKV challenge.
Antibody correlates of protection
Antibody responses were compared in both immunised and
control macaques using five independent serological assays,
summarised in Figs. 3 and 4, measuring IgG and IgM responses
to whole virus antigens and the NS-1 protein, as well as
neutralising antibody levels. In this manner serological responses
were compared pre- and post-administration of ZIKVPRVABC59 for
the four naïve controls and four macaques receiving passively
transferred human plasma.
In the four control macaques (R5, R11–R13), the total levels of
anti-Zika IgG and anti-NS-1 specific responses were remarkably
similar in the pattern of their dynamic range suggesting the
majority of the response detected by the whole virus assay was to
NS-1. In these naïve, control macaques challenged with virus, R13
and R5 developed the strongest antibody responses overall post-
ZIKV infection. All naïve, challenge controls mounted both a
neutralising antibody and an IgM response, the latter detected
using the human anti-NS-1 assay and the whole virus macaque-
specific IgM assay (Fig. 4). Anti-IgM responses were more
consistent using the total IgM assay (Fig. 4a), though there was
an exaggerated spike in anti-NS-1-specific IgM in R5 which
coincided with highest peak of vRNA in plasma recorded in this
Fig. 1 Equivalent amplification efficiency of African and Asian
lineage ZIKV by RT-qPCR. Comparison of two ZIKV RNA standard
preparations diluted in normal macaque plasma to an extinction
end-point. Amplification efficiency of RT-qPCR of ZIKVPRVABC59 (black
circles) plotted against African lineage (Ugandan 1962 MP1751) QC
material (NIBSC 16/110 expressed as IU/ml (red squares). Regression
analysis (r2 values) were 0.998 and 0.999, respectively, with a high
degree of agreement between the two reference panels. Limit of
detection (LOD) for assays was 50 RNA equivalents/mL as
described16 and 50 IU/mL.
N. Berry et al.
2













individual, further indicating the importance of this protein in the
acute response to ZIKV infection.
In contrast, neutralising antibody titres could be compared
irrespective of confounding anti-species considerations across the
entire study. All controls developed a detectable neutralising
antibody response post-ZIKV challenge, which stabilised at
400–600 IU/ml range in 3 macaques, rising to ~1700 IU/ml at
42 days after challenge in macaque R12 (Fig. 3c). In R12 this
feature was further reflected in the highest level of total and anti-
NS-1 IgG, which correlated with a slightly delayed peak and
extended shoulder of plasma vRNA (Fig. 2a). While not apparently
inducing a superior IgM response, the antigenic boost sustained
during this acute period likely accounts for the very high levels of
neutralising and binding antibody levels observed in R12. Taken
together, these de novo antibody profiles provided a comparator
to outcomes in the immunised macaques receiving passively
administered antibody.
In all recipients, 24 h following passive immunisation of the
convalescent plasma pool, broadly similar levels of total IgG to
whole virus, anti-NS-1 IgG and neutralising antibodies were
observed (Fig. 3a–c). The whole virus assay utilising an anti-
macaque antibody clearly exhibited significant cross reaction with
human anti-Zika IgG. Taken together, this indicates all macaques
received very similar levels of transferred immunoglobulin
irrespective of the assay used. Hence, on the day of challenge
anti-NS-1 IgG levels were between 175–200 relative units (RU)/mL
by ELISA and neutralisation levels were ~400 IU/ml. Whole virus
antibody titres, expressed as a ratio of normalised ODs, exhibited
similarly good reproducibility (macaques R1-R4, all ~1 normalised
OD units). Anti-Zika IgM was at or around undetectable levels in
immunised macaques at day 0 using both the total anti-Zika IgM
and anti-NS-1 assays (Fig. 4). Although a small blip in ZIKV anti-NS-
1 IgM was identified in macaque R4 in the pre-immunisation bleed
and at 14 days post-challenge, levels remained at or close to the
assay cut-off and this phenomenon was not reproduced in the
total IgM assay.
Immediately post-ZIKV challenge there was some fluctuation
noted in macaque R1 which exhibited a small boost in both
neutralising antibody, anti-NS-1, and total IgG levels, detected
3 days post administration of virus (Fig. 3a–c). As a result of this
extended peak of antibody, there was a more delayed half-life
degradation of antibody levels in R1 which were not subsequently
boosted. Similar degradation profiles were evident for R2-R4.
Comparable levels of total IgG and anti-NS-1 IgG at 42 days p.i.
(and neutralising antibody) suggest an even level of decay across
all antibody species. IgG degradation data exhibited a reduction of
IgG titres with a half-life of 2–3 weeks (Supplementary Figure 1).
Taken together there was no boost in total or anti-NS-1 ZIKV IgG
levels noted in response to viral challenge, although in R1
neutralising antibody levels transiently returned to close to their
pre-challenge levels. R4 also exhibited a weak increase in
neutralising antibodies.
Fig. 2 Viral RNA levels in plasma and tissues. a Plasma vRNA levels during acute infection during the first 40 days in naïve controls expressed
as International Units (IU) /mL. b Cell-associated ZIKV RNA levels in tissues, expressed as International Units (IU) per µg total RNA in peripheral
lymph nodes (PLN), both inguinal (ILN) and brachial (BLN), spleen, mesenteric (MLN), salivary gland and genital lymph nodes (LN). Macaque R5
was terminated 5 weeks p.i, R11, R12 at 10 weeks p.i. and R13 at 6 weeks p.i. c and d indicate plasma vRNA and tissue cell-associated RNA
levels respectively in immunised macaques (R1–R4).
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Overall, de novo antibody responses compatible with recent
infection with ZIKVPRVABC59 were not detected. On administration
of virus, the relatively rapid drop in neutralising antibody titres
(Fig. 3c) could perhaps be attributed to introduction of the
challenge virus. Interestingly, there is a slight deflection back up to
~350 IU/mL in macaque R1 but in this and all macaques there was
a subsequent, gradual decay to baseline levels. Anti-IgM responses
remained undetectable. Hence, none of the serological responses
detected are compatible with an active anti-ZIKV response in any
of the immunised macaques.
DISCUSSION
Establishing immune responses, both in terms of their quality and
quantity, that effective vaccines needs to elicit represents valuable
data that will accelerate vaccine development and subsequent
regulatory approval. Relating outcomes of model systems back to
standardised measures of vaccine protection will be important in
assessing correlates of vaccine protection elicited by different
vaccines. To address this we have utilised human convalescent
plasma derived from two ZIKV-exposed individuals during the
recent epidemic in central America, who subsequently recovered
from infection making a strong humoral immune response. This
report describes use of an NHP challenge model of ZIKV infection
where prior transfer of a human convalescent plasma pool to
recipients receiving 400 IU/mL anti-ZIKV antibodies prevents
detectable infection when challenged sub-cutaneously with 1000
pfu ZIKVPRVABC59. Passive immunisation of these human antibodies
into macaques 24 h prior to sub-cutaneous challenge with the
ZIKVPRVABC59 strain was able to confer full protection against this
contemporary ZIKV strain.
Previous studies have mainly focussed on mouse models which
have indicated high titre neutralising antibody responses to
envelope antigens are associated with a protective outcome21 and
passive immunisation with either vaccine-delivered antibodies,
virus-specific monoclonal antibodies or convalescent human
serum may be efficacious22. There is limited data, however,
relating to passive protection against ZIKV in immunocompetent
NHP systems, although one study conducted in rhesus macaques
indicates such an approach may be effective26.
Using materials from the international collaborative study used
to establish an International Standard in International Units per ml
(IU/ml), we were able to determine that a neutralising antibody
titre of 400 IU/ml was sufficient to deliver complete protection.
The protection demonstrated appeared complete, with no
evidence of ZIKV RNA in the blood or tissues, or detection of
Fig. 3 Anti-ZIKV IgG and neutralising antibodies pre and post ZIKV challenge. Sera collected over the time-course were assessed for their
anti-ZIKV activity using (a) whole virus anti-ZIKV IgG (b) binding antibody levels to anti-NS-1 IgG expressed as relative units (RU)/mL, (c)
neutralisation titres expressed in International Units (IU/mL) Treatment macaques (Group A) are depicted in green and challenge controls
(Group B) in red. Arrow indicates administration of the virus.
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antibody responses apart from those directly attributable to the
passive injection, prior to challenge with wild-type virus. As no
cellular component was transferred, this reinforces the notion that
antibodies present in the cell-free component of blood alone were
responsible for the protection. These data are very valuable for
both vaccine developers and regulators which provide a mechan-
ism of protection candidate vaccines need to replicate. In addition,
they provide some guidance on the amount of antibody required
at the time of virus challenge to confer complete protection
against detectable infection. These data may assist in establishing
the likely dosing schedule to elicit robust protection and in
addition the likely duration of protection conferred by candidate
vaccines. At the same time since a titration of the reference serum
was not performed, we do not know the lower limit of antibody
required to confer complete protection. The size, blood volume,
cost, and welfare issues of using Old World non-human primate
models of Zika virus infection may mean that alternative models
should be used to undertake these plasma/serum titration studies.
Smaller New World NHP species demonstrated to be susceptible to
ZIKV may be suitable for this purpose.
Both immunocompetent and immunodeficient mouse strains
support replication of ZIKV in vivo. It should also be noted that the
current study was conducted in cynomolgus, rather than rhesus
macaques. The peak viremia and tissue distribution of ZIKV in the
former species is less than the latter16. Thus, these studies may
overestimate the degree of protection possible with plasma/serum
alone in more susceptible NHP species. Nevertheless, the key
anatomical similarities between NHPs and humans, for example in
placental structure which indicate that some further studies of
protection should be performed in an appropriate NHP species,
particularly those evaluating protection against congenital Zika
syndrome. The role antibody transfusion plays during an active,
acute infection or as a pre-exposure prophylaxis therapy could also
be explored and would provide further valuable information,
although the timing of such intervention would be critical given
the rapid establishment of the virus immediately post-exposure
and the natural decline of antibody titres post immunisation.
Here, we have formally demonstrated complete protection from
ZIKV challenge in a model system using human polyclonal
convalescent immune serum. Complete protection is presumed
to have occurred since there were no de novo antibody responses
to ZIKV in any of the assays used and all macaques remained ZIKV
RNA genome negative. The whole virus anti-ZIKV IgG and IgM
assays which employed anti-macaque secondary antibodies failed
to detect any evidence for an acute or systemic ZIKV infection.
Rapid loss of neutralising titres on challenge were compatible with
a significant reduction in the infective potential of the inoculum,
either removing the ability of the virus to infect completely or
reducing levels to below a sub-clinical threshold. Our previous
studies characterising the early kinetics of ZIKV infection in
different NHP species, including cynomolgus macaques, demon-
strate rapid uptake and widespread dissemination of virus 3 days
p.i.16. Although it cannot be completely excluded that very low
levels of persisting sequestered virus may exist at some sites, we
found no evidence of viral RNA in either the blood or the major
lymphoid tissues sampled which would indicate this has occurred.
Coupled with lack of any sustained antigenic re-exposure the
serological data would appear to concur with this observation.
In this study, both antibody and viral challenge outcome data
were expressed with reference to International Units (IUs), paving
the way for standardisation of vaccine response data across
different studies and vaccine regimens. This important considera-
tion in determining relative vaccine efficacy and potency of
different vaccine approaches and likely ability to protect in vivo,
may ultimately obviate the need for extensive pre-clinical
challenge data to be generated for candidate vaccines. Use of
Fig. 4 Anti-ZIKV IgM levels. a whole viral antigen ELISA and b anti-NS-1 binding antibody levels to anti-Zika IgM expressed as a ratio. Arrows
indicate time of administration of ZIKVPRVABC59 at day 0. Treatment macaques (Group A) are depicted in green and challenge controls (Group
B) in red. Arrow indicates administration of the virus.
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an immunocompetent host where both immune response and
virus dissemination properties in unvaccinated, naive individuals
resembles that of ZIKV infection in humans provides a distinct
advantage over previously published studies in rodents. However,
different vaccine platforms may require a more tailored approach
although this does provide a framework for comparative studies.
On the face of it, vaccines that generate a strong neutralising
antibody response to ZIKV represent a clear goal for ZIKV
immunisation studies via active vaccination. Responses to sub-
unit components of the virus representing the external domain of
the ZIKV envelope (ZEDIII) may provide effective cross-neutralising
activity27,28. However, some caution may be needed in this area
given that cases of ZIKV-microcephaly have been strongly
correlated to ZIKV neutralising antibody responses in previously
ZIKV-naïve individuals. Prior cross-reactive antibody reactivity to
other flaviviruses do not appear to be linked to an antibody-
dependent enhancement (ADE)-related pathologic mechanism
but may be intrinsic to Zika ADE generation in naïve, susceptible
hosts. Maternal antibodies with enhanced reactivity to ZEDIII
antigens and ZIKV neutralisation per se have been strongly
associated with cases of microcephaly in the recent outbreak,
accounting for the most severe outcomes of ZIKV positive
pregnancies29. The caveat for any intervention strategy must be
that if only partial protection was attained by vaccination where
otherwise naïve subjects still became infected where a ZIKV
neutralising antibody response was generated but failed to deliver
complete protection from infection, potentiation of subsequent
infections where boosts in anti-ZIKV titres that may be deleterious
could result in adverse outcomes. Low level or non-neutralisation
titres in the context of homotypic ZIKV ADE potentiating ZIKV
pathogenesis is thus both a complex and important area30, which
may need factoring into the regulatory understanding of both
beneficial and deleterious responses. Further studies of ZIKV
immunisation should address this issue encompassing the broad-
est range of anti-ZIKV antibody responses, both in terms of quality
as well as quantity, to enable differentiation between protective
and potentially harmful anti-ZIKV responses that could be elicited
by vaccination. In future studies, inclusion of other polyclonal
immunoglobulin preparations, possibly including those from
commercial sources, would provide an opportunity to assess the
potential role of non-ZIKV specific antibodies with the potential to
block viral epitopes.
The data presented here establish the potential for a human
convalescent plasma reference material to calibrate the threshold
levels of anti-ZIKV antibodies needed for vaccine protection in an
NHP model. These data may enable effective standardisation of
vaccine potency that will permit meaningful comparison between
different vaccine strategies designed to generate protective
immunity, identified as a key part of vaccine development31. This
will lead to harmonised evaluation of candidate vaccines and the
accelerated regulatory approval of safe, efficacious vaccines
against Zika virus. Combined with sera/plasma from human
clinical trials clarification of protective efficacy would certainly
facilitate candidate vaccine evaluation. This approach may prove
to be particularly useful in the screening of the raft of vaccines
currently being developed to the SARS-CoV-2 coronavirus and
perhaps other emerging viruses, to a provide scientific basis and
rationale for the selection of the most promising vaccines.
METHODS
Ethical statement
All animal procedures were performed in strict accordance with UK Home
Office guidelines, under licence 70/8953 granted by the Secretary of State
for the Home Office which approved the work described, in accordance
with local ethical guidelines and internal committee approval for animal
welfare at NIBSC. This study conforms to all relevant ethical regulations for
animal work in the UK. Purpose-bred, juvenile cynomolgus macaques
(Macaca fascicularis) were group housed for the duration of the study, with
daily feeding and access to water ad libitum. Regular modifications to the
housing area and environmental enrichment of all study NHPs were made
by husbandry staff. Environmental temperature was appropriate for
macaque species and rooms subject to 12 hr day/night cycles of lighting.
Animals were acclimatised to their environment and deemed healthy by
the named veterinary surgeon prior to inclusion on the study. All surgical
procedures were performed under anaesthesia with recovery.
Study design
Eight juvenile Mauritian-origin cynomolgus macaques were used accord-
ing to ethical guidelines. Antibody sourced for the study was a pool of
polyclonal convalescent plasma obtained from two donors originating in
the Dominican Republic, supplied by Boca Biolistics Ltd, Florida, USA. This
material had been pre-prepared as an anti-Zika working reagent (NIBSC 16/
320) whereby multiple lyophilised vials were reconstituted to derive a pool
of convalescent plasma, characterised as part of a collaborative study of
anti-Zika antibodies23. Results from this collaborative study assigned a
value of 2756 IU/mL (95% confidence limits of 2003 to 3792 IU/mL). A total
of 25 mL of reconstituted plasma was administered intra-peritoneally (i.p.)
into each of four cynomolgus macaques weighing 2.2–2.4 kg. Intra-
peritoneal injection was used to obviate the need to concentrate the Ig
fraction and administer serum/plasma at volumes achieving circulating
anti-Zika antibody concentrations 1:2 to 1:4 of that in the administered
plasma with an uptake within 24 h post administration. All four, and an
additional four naïve challenge controls were subsequently administered
with 103 Pfu/mL of the PRVABC59 Zika isolate via the subcutaneous route
as previously described16, representing a biologically relevant challenge32.
Calculations were according to accepted criteria, assuming a circulating
volume of 66mL/kg for cynomolgus macaques33.
Quantitative RT-qPCR for ZIKV RNA in plasma
Quantitative RT-qPCR was performed on total RNA extracted from 140ul
plasma as previously described16. The limit of detection for the RT-qPCR
was 50 RNA IU/mL of plasma, determined by end-point analysis of target
molecules. All data were visualised using the SigmaPlot v12 statistical
package.
Cell-associated ZIKV levels in tissues
Total RNA (100 ng) isolated from selected tissues samples of peripheral
lymph nodes ILN, BLN), spleen, MLN, salivary gland LN, and genital LN were
subjected to RT-qPCR, normalised to GAPDH, as previously described16.
Data were expressed as IU/µg total RNA with a limit of detection of 20 IU/
µg total RNA.
Anti-Zika serology
Anti-Zika neutralising antibodies were determined as previously
described16, with values expressed as International Units per mL (IU/mL)
serum. Anti-NS-1 IgG and IgM levels were determined using commercially
available assays (EuroImmune Ltd), performed according to the manu-
facturer’s instructions. Total anti-Zika responses to whole virus antigens
were also assessed. In brief, EIA plates (Nunc, Maxisorb) were coated
overnight at 4 °C with whole virus ZIKVPRVABC59 supernatant diluted in
phosphate buffered saline (PBS) representing a concentration of 1 × 105
pfu/mL, fixed with 4% paraformaldehyde for 30min at RT °C. Supernatant
from uninfected Vero E6 cells represented control antigens. Plates were
washed, blocked with 10% FCS in PBS for 1 h at RT °C, washed with PBS/
0.05% Tween-20. Samples were diluted 1:50 in 10% FCS/PBS blocking
buffer, added to the plate, incubated for 1 h at RToC and washed (x3) in
PBS-0.05% Tween-20. Secondary antibody detection was with anti-
macaque IgG or anti-macaque IgM-(μ-chain specific) conjugated to
horseradish peroxidase (Sigma Ltd), diluted 1:2000 or 1:5000 respectively
in 5% FCS in PBS and incubated for 1 h at RT °C. Unbound secondary
antibody was removed by washing (x3) with PBS-0.05% Tween-20 and
visualised by addition of TMB for 5 mins; reactions were stopped by
addition of 2 M H2SO4. Absorbance was read at 450 nM. Normalised optical
density (OD) readings were derived by subtracting control from test
antigens.
N. Berry et al.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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(and its supplementary information files).
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